Battle test
The claims this business rests on, and the hardest things anyone could say against it. Marking what you have tested moves the verdict.
What has to be true
Numbered from riskiest to safest: the ones the business depends on most and knows least about come first.
- 1
Clinics with 2 to 15 doctors can be sold without a long enterprise procurement cycle.
Execution lens. Importance 5 of 5, uncertainty 4 of 5.
- Cheapest test
- Run 20 new outbound demos and measure time from first meeting to paid conversion.
- Stop if
- Median sales cycle exceeds 45 days or most deals stall on legal, IT, or committee review.
- 2
Hindi and Tamil dictation will be accurate enough to be useful in real consultations.
Execution lens. Importance 5 of 5, uncertainty 4 of 5.
- Cheapest test
- Benchmark the feature on 50 real or recorded consultations in each language and compare edit time against English.
- Stop if
- Doctors spend more time correcting notes than they save, or they reject the output in routine visits.
- 3
Customer acquisition cost will stay low enough as you scale beyond early adopters.
Economics lens. Importance 5 of 5, uncertainty 4 of 5.
- Cheapest test
- Track CAC by channel for the next 15 wins and compare to cohort retention after 60 days.
- Stop if
- CAC rises materially while payback stretches beyond the current 8.9 months.
- 4
You can launch in India, Dubai, and Singapore without a compliance burden that overwhelms a small team.
Exposure lens. Importance 4 of 5, uncertainty 4 of 5.
- Cheapest test
- Have counsel or a specialist map the minimum regulatory path for each market and estimate launch steps, documents, and turnaround time.
- Stop if
- Any market requires product changes, certifications, or licensing work that you cannot complete with your current team and budget.
- 5
Independent clinic doctors will keep paying subscription fees after the novelty wears off because the product saves enough time every day.
Problem lens. Importance 5 of 5, uncertainty 3 of 5.
- Cheapest test
- Interview 10 paying doctors and ask them to show the exact weekly workflow change they now rely on, then check renewal intent after a 30-day usage review.
- Stop if
- More than half say they would stop if the product disappeared tomorrow, or they cannot name a specific daily time saving.
- 6
A licensed local partner in Dubai will actually open distribution rather than just add legal complexity.
Exposure lens. Importance 4 of 5, uncertainty 3 of 5.
- Cheapest test
- Get two written partner proposals that include named clinic introductions, pricing, and implementation support.
- Stop if
- Partners only offer shell access, no real leads, or demand margins that make the business unattractive.
- 7
Monthly churn will fall as the product becomes embedded in clinic workflows.
Economics lens. Importance 4 of 5, uncertainty 3 of 5.
- Cheapest test
- Compare churn and usage of the first 20 customers versus the latest 20 customers.
- Stop if
- Newer cohorts churn at the same or worse rate than the first cohorts.
The hardest objections
1 objection that could end the business has no answer yet. That holds the verdict back.
You run out of cash before breakeven
Could end itYour own model shows about 8.6 months of runway on cash in hand and break-even only at month 24. If fundraising slips or growth decelerates, the business needs a bridge before it reaches operating self-sufficiency.
Big competitors can crush you
SeriousAbridge, Nuance DAX, and similar vendors have far more capital, brand trust, and enterprise relationships. If they decide to push downmarket or bundle scribes into broader clinical software, they can outspend you and force price pressure before you build a moat.
Small clinics can buy cheaper tools
SeriousMany small practices will choose a lower-priced scribe, generic dictation, or an EHR add-on if it is good enough. If you cannot show a clear workflow advantage, your premium over simpler tools is fragile.
Regional language support may disappoint
SeriousHindi and Tamil are not just translation tasks. Clinical speech, accents, code-switching, and specialty terms can make note quality poor enough that doctors stop trusting the product. That would damage both retention and referrals.
Regulation will slow every country
ModerateIndia, Singapore, and the UAE can each impose different software, health-data, and local licensing requirements. If each launch needs special review, your three-country plan becomes a sequence of compliance projects instead of a product rollout.
Clinics are harder to sell than you think
ModerateEven without a hospital IT team, small clinics can still be cautious about workflow change, patient privacy, and doctor adoption. A good demo does not prove a clinic will standardize on the product across all doctors.